•  
  •  
 

Document Type

Original Article

Abstract

Background: Hepatocellular carcinoma (HCC) is the fifth-leading cause of cancer-related deaths globally. Liver biopsy is the gold standard for diagnosing liver fibrosis and cirrhosis. Instead of a liver biopsy, a number of noninvasive diagnostic tools for assessing hepatic fibrosis as a risk factor for HCC, such as fibroscan. Aim of work: Assess the role of Transient Elastography (Fibroscan) in prediction of (HCC) in chronic hepatitis C virus patients. Subjects and methods: A case-control study included 133 patients with cirrhosis and HCC and 133 patients with HCV-Liver cirrhosis without HCC was carried out. Each patient had their medical history taken, and thorough clinical examination, they were assessed for liver stiffness using fibroscan, all patients underwent Triphasic CT scan, routine laboratory investigations were taken from each patient as liver function test, CBC and tumor markers. Results: Males resembled the majority and patients with HCC were significantly older than those without HCC (p-value < 0.001). Our data showed that sensitivity analysis of liver stiffness measured by transient elastography (FibroScan) can be used to discriminate between cirrhotic group without HCC and HCC group at a cutoff level of > 24.3, with 90.5% sensitivity, 85.7% specificity, 86.4% PPV and 90% NPV (AUC = 0.941 & p-value less than 0.001). Conclusion: Fibroscan can significantly predict HCC among patients post-HCV treatment using cutoff point of liver stiffness > 24.3 kPa.

Keywords

HCC; Fibroscan; Liver stiffness; Cirrhosis

Download

Share

COinS